Ireland - English - HPRA (Health Products Regulatory Authority)

zoetis ireland limited - lincomycin - solution for injection - 100 mg/ml - lincomycin - canine, feline, porcine - antibacterial

Ireland - English - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - lincomycin - solution for injection - 100 mg/ml - canine - antibacterial

Ireland - English - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - lincomycin - solution for injection - 100 mg/ml - antibacterial - canine feline porcine

Ireland - English - HPRA (Health Products Regulatory Authority)

zoetis belgium s.a. - lincomycin hydrochloride - solution for injection - 100 milligram(s)/millilitre - lincomycin - cats, dogs, pigs - antibacterial

United Kingdom - English - VMD (Veterinary Medicines Directorate)

zoetis uk limited - lincomycin - solution for injection - antimicrobial - cats, dogs, pigs

Ireland - English - HPRA (Health Products Regulatory Authority)

zoetis ireland limited - lincomycin hydrochloride neomycin sulfate - intramammary solution - 330/100 mg/syringe - antibacterial - bovine

United States - English - NLM (National Library of Medicine)

zoetis inc. - lincomycin hydrochloride (unii: m6t05z2b68) (lincomycin - unii:bod072yw0f) - lincocin products are indicated in infections caused by gram-positive organisms which are sensitive to its action, particularly streptococci and staphylococci. the drug has proven effective in eradicating causative organisms in most of the common upper respiratory tract infections, in septicemia, and in infections of the skin and adjoining tissues. systemic therapy with lincocin has been shown to be of benefit in many animals with pustular dermatitis. as with all antibiotics, in vitro sensitivity studies should be performed before lincocin is utilized as sole antibiotic therapy. lincocin has been demonstrated to be effective in the treatment of staphylococcal infections resistant to other antibiotics and sensitive to lincomycin. the drug may be administered in combination therapy with other antimicrobial agents when indicated. no serious hypersensitivity reactions have been reported and many animals have received lincocin repeatedly without developing evidence of hypersensitivity. lincocin has demonstrated e

United States - English - NLM (National Library of Medicine)

pharmacia & upjohn company llc - lincomycin hydrochloride (unii: m6t05z2b68) (lincomycin - unii:bod072yw0f) - lincomycin 300 mg in 1 ml - lincocin is indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. because of the risk of cdad, as described in the boxed warning , before selecting lincomycin the physician should consider the nature of the infection and the suitability of other alternatives. indicated surgical procedures should be performed in conjunction with antibacterial therapy. lincocin may be administered concomitantly with other antimicrobial agents when indicated. lincocin is not indicated in the treatment of minor bacterial infections or viral infections. to reduce the development of drug-resistant bacteria and maintain the effectiveness of lincocin and other antibacterial drugs, lincocin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

Canada - English - Health Canada

sandoz canada incorporated - clindamycin (clindamycin phosphate) - solution - 150mg - clindamycin (clindamycin phosphate) 150mg - lincomycins

Canada - English - Health Canada

fresenius kabi canada ltd - clindamycin (clindamycin phosphate) - solution - 150mg - clindamycin (clindamycin phosphate) 150mg - lincomycins